Antibodies can provide a more specific means of inhibiting TLR2 and 4; indeed, MTS510, a monoclonal antibody, has already been used to inhibit TLR4 expression in ischemic [61] and hemorrhagic stroke [27,62] in preclinical models. The gene discussed is TLR2; the disease is hemorrhagic stroke.